Condition (MeSH)
Ichthyosiform Erythroderma, Congenital
ClinicalTrials.gov lists 30 trials for Ichthyosiform Erythroderma, Congenital or a narrower condition beneath it. Quoin Pharmaceuticals has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 30 trials are tagged with Ichthyosiform Erythroderma, Congenital itself; the rest are tagged with a narrower condition beneath it.
When did Ichthyosiform Erythroderma, Congenital trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2016 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ichthyosiform Erythroderma, Congenital trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 4 |
| Phase 2 | 3 |
| Phase 2/3 | 7 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 6 |
How many Ichthyosiform Erythroderma, Congenital trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 14 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ichthyosiform Erythroderma, Congenital trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Quoin Pharmaceuticals | 4 |
| Daiichi Sankyo | 3 |
| Boehringer Ingelheim | 2 |
| Azitra Inc. | 1 |
| BioCryst Pharmaceuticals | 1 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Ichthyosiform Erythroderma, Congenital? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DS-2325a | 3 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Secukinmab | 2 |
| QRX003, 4% Lotion | 2 |
| QRX003 | 1 |
| BPR277 ointment | 1 |
| BLOOD SAMPLES | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ichthyosiform Erythroderma, Congenital trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hospitalization-GERD | 2 | 1 |
| Abortion spontaneous | 1 | 1 |
| Anaphylactic reaction | 1 | 1 |
| Basal cell carcinoma | 1 | 1 |
| Chronic sinusitis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Ichthyosiform Erythroderma, Congenital? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Secukinumab responses vary across the spectrum of congenital ichthyosis in adults. | Archives of dermatological research | 2023 | Yes |
| Novel transglutaminase-1 mutations and genotype-phenotype investigations of 104 patients with autosomal recessive congenital ichthyosis in the USA. | Journal of medical genetics | 2009 | Yes |
| Transglutaminase-1 gene mutations in autosomal recessive congenital ichthyosis: summary of mutations (including 23 novel) and modeling of TGase-1. | Human mutation | 2009 | Yes |
| LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. | Human molecular genetics | 2003 | Yes |
| The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. | The Journal of investigative dermatology | 2001 | Yes |
Showing 5 of 6 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.